Form 8-K - Current report:
SEC Accession No. 0000950170-25-063975
Filing Date
2025-05-06
Accepted
2025-05-06 08:00:11
Documents
13
Period of Report
2025-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vera-20250506.htm   iXBRL 8-K 53319
2 EX-99.1 vera-ex99_1.htm EX-99.1 153440
3 GRAPHIC img47757703_0.jpg GRAPHIC 265803
  Complete submission text file 0000950170-25-063975.txt   681422

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vera-20250506.xsd EX-101.SCH 25972
15 EXTRACTED XBRL INSTANCE DOCUMENT vera-20250506_htm.xml XML 4723
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005 650-770-0077
Vera Therapeutics, Inc. (Filer) CIK: 0001831828 (see all company filings)

EIN.: 812744449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40407 | Film No.: 25915296
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)